Search for

Search Results

96 Search Results

Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report

The American Society of Clinical Oncology (ASCO) has named “refinement of the surgical treatment of cancer” as the 2020 Advance of the Year within the field of oncology clinic research. This announcement was made in “Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology,” which was published […]

Unique Toronto-based clinical trial reveals new subtypes of advanced pancreatic cancer

Researchers identify five subtypes of pancreatic cancer, uncovering new opportunities for targeted treatment of the aggressive disease. Researchers at the Ontario Institute for Cancer Research (OICR) and the University Health Network (UHN) have discovered detailed new information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment […]

U-M Team Sheds New Light on the Role of Regulatory T Cells in Pancreatic Cancer

In mouse models, the work uncovers a new potential target to improve immunotherapy approaches to the deadly disease. A multidisciplinary Michigan Medicine team is shedding new light on the role of regulatory T cells in pancreatic cancer — and, in mouse models, have uncovered a new potential target to improve immunotherapy approaches to the deadly […]

New Procedure Saves Lives Through Early Pancreatic Cancer Detection

Overall cancer survival has dramatically improved over the past two decades. However, the prognosis for pancreatic cancer remains bleak, with five-year survival at just 9 percent. Patients usually don’t have symptoms until the cancer is advanced, making early diagnosis and treatment a challenge. Now, a study by researchers at The Ohio State University Wexner Medical […]

Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer

Lynparza reduced the risk of disease progression or death by 47% in patients whose disease had not progressed on at least 16 weeks of a 1st-line platinum-based chemotherapy regimen Only PARP inhibitor approved in germline BRCA-mutated metastatic pancreatic cancer AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the […]

AstraZeneca Says FDA Panel Backs Lynparza Use For Pancreatic Cancer

AstraZeneca and Merck & Co., said that the US Food and Drug Administration Oncologic Drugs Advisory Committee voted 7 to 5 to recommend Lynparza or olaparib as a 1st-line maintenance monotherapy for patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas (pancreatic cancer), whose disease has not progressed following 1st-line platinum-based chemotherapy. In August 2019, […]

Back to Top